BioMarin achondroplasia treatment granted orphan designation by EMA Orphan designation granted by the European Commission to BioMarin Europe for modified recombinant human C-type natriuretic peptide for the treatment of achondroplasia on Jan. 24, according to posting to European Medicines Agency site. Reference Link
BioMarin price target raised to $104 from $90 at William Blair William Blair raised its price target for BioMarin shares to $104 following the company's R&D day and keeps an Outperform rating on the stock. The firm expects the Vimizim launch to remain strong and believes BioMarin holds one of the strongest pipelines in the sector.
Piper Jaffray biopharm analyst holds an analyst/industry conference call Senior Research Analyst Schimmer, along with Biopharmaceuticals Analyst Breazzano, discuss gene therapy for hemophilia on an Analyst/Industry conference call to be held on December 11 at 10 am.